SEC Comment Letter for Q32 Bio Inc. (QTTB) (CIK 0001661998) (QTTB) — Apr 8, 2019
Q32 Bio Inc. (QTTB) (CIK 0001661998)
Date: April 8, 2019 · CIK: 0001661998 · Accession: 0000000000-19-006752
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-230664
Letter
April 8, 2019 Arthur O. Tziannabos President and Chief Executive Officer Homology Medicines, Inc. One Patriots Park Bedford, MA 01730 Re:Homology Medicines, Inc. Registration Statement on Form S-3 Filed April 1, 2019 File No. 333-230664 Dear Dr. Tziannabos: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Christine Westbrook at 202-551-5019 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Wesley C. Holmes, Esq.
Show Raw Text
April 8, 2019
Arthur O. Tziannabos
President and Chief Executive Officer
Homology Medicines, Inc.
One Patriots Park
Bedford, MA 01730
Re:Homology Medicines, Inc.
Registration Statement on Form S-3
Filed April 1, 2019
File No. 333-230664
Dear Dr. Tziannabos:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Christine Westbrook at 202-551-5019 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Wesley C. Holmes, Esq.